Search Result

Results for "

and HDAC8

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) AMPK (2) Apoptosis (33) Autophagy (10) Bcl-2 Family (1) Beta-lactamase (5) Biochemical Assay Reagents (1) Casein Kinase (1) Caspase (2) DNA/RNA Synthesis (1) Epigenetic Reader Domain (1) FGFR (1) Guanylate Cyclase (1) HDAC (96) Histone Demethylase (3) iGluR (1) Ligands for Target Protein for PROTAC (1) MDM-2/p53 (1) Microtubule/Tubulin (3) Mitochondrial Metabolism (2) Necroptosis (1) p38 MAPK (1) Parasite (7) PI3K (1) Pim (1) PPAR (1) PROTACs (5) Proteasome (1) Reactive Oxygen Species (ROS) (3) Small Interfering RNA (siRNA) (3) Survivin (1) Topoisomerase (2) VD/VDR (1)
By Research Areas:	Cancer (82) Cardiovascular Disease (1) Infection (10) Inflammation/Immunology (4) Metabolic Disease (1) Neurological Disease (4)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

100

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Click Chemistry

Oligonucleotides

Targets Recommended: Fat Mass and Obesity-associated Protein (FTO)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-111342

HDAC8-IN-1 3 Publications Verification	HDAC	Cancer
HDAC8-IN-1 is a *HDAC8* inhibitor with an IC₅₀ of 27.2 nM.

HY-153583

HDAC8-IN-4	HDAC	Cancer
HDAC8-IN-4 is a selective inhibitor of *HDAC8. HDAC8-IN-4* inhibits HDAC8 and HDAC3 with IC₅₀s of 0.15 and 12 μM .

HY-149529

HDAC8-IN-5	HDAC	Cancer
HDAC8-IN-5 (Compound 6a) is a *HDAC8* inhibitor (IC₅₀: 28 nM). HDAC8-IN-5 can be used for cancer research .

HY-163143

HDAC8-IN-6	HDAC	Cancer
HDAC8-IN-6 (compound 3) is a potent *HDAC8* inhibitor with an IC₅₀ of 5.1 μM. HDAC8-IN-6 shows cytotoxicity .

HY-163846

HDAC8-IN-10	HDAC	Cancer
HDAC8-IN-10 (compound 15) is a potent inhibitor of *HDAC8, with the IC₅₀* of 7.6 nM. HDAC8-IN-10 is a *HDAC8* target protein ligand that can be used to synthesize PROTAC YX862 (HY-163845) .

HY-111027

HDAC8-IN-13	Apoptosis	Infection
HDAC8-IN-13 is a novel histone deacetylase 8 (HDAC8) inhibitor with antiparasitic activity. HDAC8-IN-13 can effectively inhibit the acetyl-L-lysine deacetylase activity of schistosomes, affecting the parasite's infectivity. HDAC8-IN-13 can induce apoptosis and cause the death of schistosome cells. Through a specific structural basis design, HDAC8-IN-13 exhibits reduced affinity for human HDACs, thereby enhancing its selectivity .

HY-151366

HDAC8/BRPF1-IN-1	HDAC Epigenetic Reader Domain	Cancer
HDAC8/BRPF1-IN-1 (Compound 23a) is a dual inhibitor of *HDAC8* and BRPF1 with an IC₅₀ of 443 nM against human HDAC8 and a K_d of 67 nM against human BRPF1. HDAC8/BRPF1-IN-1 shows low in vitro activity against HDAC1 and 6 .

HY-147934

HDAC8-IN-3	HDAC Apoptosis	Cancer
HDAC8-IN-3 (compound P19) is a potent *HDAC8* inhibitor with IC₅₀ value of 9.3 μM and produces thermal stabilization. HDAC8-IN-3 has cytotoxicity and induces apoptosis in leukemic cell lines .

HY-144098

HDAC8-IN-2	Parasite HDAC	Others
HDAC8-IN-2 (compound 5o) is a potent *HDAC8* inhibitor, with IC₅₀ values of 0.27 and 0.32 μM for smHDAC8 (Schistosoma mansoni histone deacetylase 8) and hHDAC8, respectively. HDAC8-IN-2 shows significant killing of the schistosome larvae. HDAC8-IN-2 markedly impairs egg laying of adult worm pairs .

HY-178380

HDAC8-IN-14	HDAC Reactive Oxygen Species (ROS) Apoptosis Necroptosis Biochemical Assay Reagents Caspase Bcl-2 Family	Inflammation/Immunology Cancer
HDAC8-IN-14, a curcuminoid derivative, is a selective *HDAC8* inhibitor with a Ki of 9 nM. HDAC8-IN-14 induces the production of reactive oxygen species (ROS), disrupts mitochondrial membrane potential, and promotes apoptosis. HDAC8-IN-14 can significantly promote the accumulation of cells in the sub-G0/G1 phase, consistent with apoptotic or necrotic cell death. HDAC8-IN-14 induces upregulation of cytochrome c, cleaved caspase-3, and the pro-apoptotic protein Bak while leaving the anti-apoptotic Bcl-2 levels unaltered. HDAC8-IN-14 can be used for the study of leukemia .

HY-161465

HDAC8-IN-7	HDAC	Inflammation/Immunology
HDAC8-IN-7 (H7E), a *HDAC8* inhibitor, exerts retinoprotective effects against glaucomatous injury via ameliorating aberrant Müller glia activation and oxidative stress. HDAC8-IN-7 alleviates functional and structural defects within the inner retina .

HY-161954

HDAC8-IN-12	HDAC	Cancer
HDAC8-IN-12 (compound 5k) is a non-hydroxamic acid, selective inhibitor of *HDAC8* (IC₅₀: 0.12 nM) and a potent inhibitor of breast cancer. HDAC8-IN-12 triggers anti-tumor immunity by activating T cells, increasing the proportion of M1 macrophages and decreasing the proportion of M2 macrophages. HDAC8-IN-12 (50 mg/kg) exerts tumor suppressive effects in an orthotopic mouse model of breast cancer .

HY-168176

HDAC8 ligand 1	PROTACs HDAC	Cancer
HDAC8 ligand 1 is a PROTAC target protein-ligand of PROTAC HDAC8 Degrader-2 (HY-168174) .

HY-124782

HDAC8-IN-8	HDAC	Infection
HDAC8-IN-8 (15a) is an *HDAC8* inhibitor, with IC₅₀ values of 23.9 μM and 268.2 μM for hHDAC8 and smHDAC8 respectively. And for hHDAC1 and hHDAC6, the IC₅₀ values are 12.1 μM and 2.9 μM respectively. HDAC8-IN-8 can be used in schistosomiasis-related research .

HY-163921

HDAC8-IN-11	Ligands for Target Protein for PROTAC	Cancer
HDAC8-IN-11 is a ligand for target protein for pROTAC.

HY-111028

J1038 T 5979345	HDAC	Infection
J1038 (T 5979345) is a selective *HDAC8* inhibitor. J1038 binds the catalytic zinc ion of Schistosoma mansoni HDAC8 (smHDAC8) .

HY-163845

YX862	PROTACs HDAC	Cancer
YX862 is a selective *HDAC8* PROTAC degrader and induces the degradation of *HDAC8* with maximum degradation ＞ 95% at 250 nM in MDA-MB-231 cells(Sturcture Note:(Blue: VHL E3 ligand (HY-112078), Black: linker；Pink: HDAC8 inhibitor (HY-163846)) .

HY-RS06087

HDAC8 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) HDAC	Others
HDAC8 Rat Pre-designed siRNA Set A contains three designed siRNAs for HDAC8 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HDAC8 Rat Pre-designed siRNA Set A HDAC8 Rat Pre-designed siRNA Set A

HY-RS06086

Hdac8 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) HDAC	Others
Hdac8 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Hdac8 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Hdac8 Mouse Pre-designed siRNA Set A Hdac8 Mouse Pre-designed siRNA Set A

HY-RS06085

HDAC8 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) HDAC	Others
HDAC8 Human Pre-designed siRNA Set A contains three designed siRNAs for HDAC8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HDAC8 Human Pre-designed siRNA Set A HDAC8 Human Pre-designed siRNA Set A

HY-178970

HDAC11-IN-4	HDAC	Cancer
HDAC11-IN-4 is a potent and selective *HDAC11* inhibitor with an IC₅₀ of 13.49 nM and a K_i of 2.2 nM. HDAC11-IN-4 exhibits extremely high selectivity for HDAC11 over other defatty-acylases such as SIRT2, SIRT3, SIRT6, and HDAC8 (SI >10,000). HDAC11-IN-4 can be used for the research of cancer .

HY-117093

H8-A5	HDAC	Cancer
H8-A5 is a novel human histone deacetylase 8 (HDAC8) inhibitor. A highly specific ZBG-based pharmacophore model was developed by incorporating a custom zinc-binding group (ZBG) feature. Pharmacophore-based virtual screening identified three novel HDAC8 inhibitors with low micromolar IC50 values (1.8-1.9 μM). Further studies showed that H8-A5 was more selective for HDAC8 than HDAC1/4 and exhibited antiproliferative activity in MDA-MB-231 cancer cells. Molecular docking and molecular dynamics studies showed that H8-A5 could bind to HDAC8, providing a good starting point for the development of HDAC8 inhibitors for cancer treatment.

HY-119586

LG190119	VD/VDR	Cancer
J1075 is a selective Schistosoma mansoni *HDAC8* modulator (with decreased affinity for human *HDAC8). J1075 can induce apoptosis (Apoptosis*) and death in schistosome cells. J1075 holds research value in the field of anti-parasitic agents .

HY-119550

J1075	HDAC Parasite	Infection
J1075 is a selective Schistosoma mansoni *HDAC8* inhibitor (with decreased affinity for human *HDAC8). J1075 can induce apoptosis (Apoptosis*) and death in schistosome cells. J1075 holds research value in the field of anti-parasitic agents .

HY-126829

Coumarin-SAHA	HDAC	Cancer
Coumarin-SAHA is a fluorescent probe for determining the binding affinities (k_d) and the dissociation off-rates (k_off) of the HDAC8-inhibitor complexes .

HY-117348

NCC-149	HDAC	Neurological Disease
NCC-149 is a selective *HDAC8* inhibitor and can be used for neural differentiation research .

HY-168175

*PROTAC HDAC8* Degrader-2**	PROTACs HDAC	Cancer
PROTAC HDAC8 Degrader-2 (compound 32a) is a degrader of HDAC8 with a DC₅₀ of 8.9 nM and HDAC6 with a DC₅₀ of 14.3 nM. PROTAC HDAC8 Degrader-2 is composed of PROTAC target protein ligand HDAC8 ligand 1 (HY-168176) (red part), E3 ligase ligand Thalidomide-4-OH (HY-103596) (blue part) and PROTAC Linker 1,5-Diaminopentane (HY-W540541) (black part), among which the conjugate of E3 ubiquitin ligase ligand + Linker is Thalidomide-NH-C5-NH2 (HY-134986) .

HY-18700

BRD73954 4 Publications Verification	HDAC	Cancer
BRD73954 is a potent *HDAC* inhibitor and selectively inhibiting both HDAC6 and HDAC8 with IC₅₀ values of 0.0036, 0.12, 9, 12, 23 µM for HDAC6, HDAC8, HDAC2, HDAC1 and HDAC3, respectively. BRD73954 decreases the levels of HDAC6, associated with upregulation of Ac-Tubulin .

HY-19754A

CRA-026440 hydrochloride	HDAC Apoptosis	Cancer
CRA-026440 hydrochloride is a potent, broad-spectrum *HDAC* (HDAC) inhibitor. The K_i values against recombinant HDAC isoenzymes *HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, and HDAC10* are 4 nM, 14 nM, 11 nM, 15 nM, 7 nM, and 20 nM respectively. CRA-026440 hydrochloride shows antitumor and antiangiogenic activities . CRA-026440 (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-15224

PCI-34051 25+ Cited Publications	HDAC Apoptosis	Cancer
PCI-34051 is a potent and selective *HDAC8* inhibitor with IC₅₀ of 10 nM, with >200-fold selectivity over the other HDAC isoforms.

HY-163920

*PROTAC HDAC8* Degrader-1**	PROTACs HDAC	Cancer
Degrader-1 (compound Z16) is a potent and selective *HDAC8* PROTAC degrader with an DC₅₀ of 0.27 nM in A549 cells .

HY-130538

1-Naphthohydroxamic acid 2 Publications Verification	HDAC	Cancer
1-Naphthohydroxamic acid (Compound 2) is a potent and selective *HDAC8* inhibitor with an IC₅₀ of 14 μM. 1-Naphthohydroxamic acid is more selectively for *HDAC8* than class I HDAC1 and class II HDAC6 (IC₅₀ >100 μM). 1-Naphthohydroxamic acid does not increase global histone H4 acetylation and also does not reduce total intracellular HDAC activity .1-Naphthohydroxamic acid can induce tubulin acetylation .

HY-150772

*Tubulin/HDAC-IN-1*	Microtubule/Tubulin HDAC Apoptosis Mitochondrial Metabolism	Cancer
Tubulin/HDAC-IN-1 is a dual tubulin and *HDAC-IN-1* inhibitor through CH/π interaction with tubulin and hydrogen bond interaction with HDAC8. Tubulin/HDAC-IN-1 inhibits tubulin polymerization and selectively inhibits HDAC8 (IC₅₀: 150 nM). Tubulin/HDAC-IN-1 has cytotoxicity against various human cancer cells, also arrests cell cycle in the G2/M phase and induces cell apoptosis. Tubulin/HDAC-IN-1 can be used in the research of hematologic and solid tumors such as neuroblastoma, leukemia .

HY-14718A

Resminostat hydrochloride 3 Publications Verification RAS2410 hydrochloride; 4SC-201 hydrochloride	HDAC	Cancer
Resminostat hydrochloride is a potent inhibitor of *HDAC1, HDAC3* and *HDAC6, with mean IC₅₀* values of 42.5, 50.1, 71.8 nM, respectively, and shows less potent activities against HDAC8, with an IC₅₀ of 877 nM.

HY-112908

RTS-V5	HDAC Proteasome	Cancer
RTS-V5 is a dual *HDAC/proteasome* inhibitor with IC₅₀s of 6.9, 18, 15, 0.27, 0.53 μM for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, respectively.

HY-119017

SB-429201	HDAC	Cancer
SB-429201 is a potent and selective *HDAC1* (IC₅₀~1.5 μM). SB-429201 displays at least a 20-fold preference for HDAC1 inhibition over HDAC3 and HDAC8 .

HY-111400

SR-4370	HDAC	Cancer
SR-4370 is an inhibitor of *HDAC, with IC₅₀s of 0.13 μM, 0.58 μM, 0.006 μM, 2.3 μM, and 3.4 μM for HDAC1, HDAC2, HDAC3, HDAC8, and HDAC*6, respectively.

HY-152147

SZUH280	PROTACs HDAC Apoptosis DNA/RNA Synthesis	Cancer
SZUH280 is a potent and selective PROTAC HDAC8 degrader with a DC₅₀ of 0.58 μM in A549 cells. SZUH280 induces cancer cell apoptosis. SZUH280 hampers DNA damage repair in cancer cells, promoting cellular radiosensitization .

HY-18947

SKLB-23bb	HDAC	Cancer
SKLB-23bb is a potent and selective inhibitor for *HDAC6* with an IC₅₀ of 17 nM and shows 25-fold and 200-fold selectivity relative to *HDAC1* (IC₅₀=422 nM) and *HDAC8* (IC₅₀=3398 nM), respectively.

HY-157314

HDAC6-IN-27	HDAC Parasite	Infection
HDAC6-IN-27 (compound 8C) is a *HDAC* inhibitor with IC₅₀ vales of 15.9 nM 136.5 nM and 6180.2 nM for HDAC6, HDAC8 and HDAC1, respectively. HDAC6-IN-27 shows potent antiparasitic effects .

HY-14718

Resminostat 3 Publications Verification RAS2410; 4SC-201	HDAC	Cancer
Resminostat (RAS2410; 4SC-201) is a potent inhibitor of *HDAC1, HDAC3* and *HDAC6, with mean IC₅₀* values of 42.5, 50.1, 71.8 nM, respectively, and shows less potent activities against HDAC8, with an IC₅₀ of 877 nM.

HY-114483

AES-135 1 Publications Verification	HDAC	Cancer
AES-135, a hydroxamic acid-based pan-HDAC inhibitor, prolongs survival in an orthotopic mouse model of pancreatic cancer. AES-135 inhibits HDAC3, HDAC6, HDAC8, and HDAC11 with IC₅₀s ranging from 190-1100 nM .

HY-15994

Citarinostat 3 Publications Verification ACY241	HDAC	Cancer
Citarinostat (ACY241) is a second generation potent, orally active and high-selective *HDAC6* inhibitor with an IC₅₀ of 2.6 nM (IC₅₀s of 35 nM, 45 nM, 46 nM and 137 nM for HDAC1, HDAC2, HDAC3 and HDAC8, respectively). Citarinostat has anticancer effects .

HY-13267

Droxinostat 3 Publications Verification NS 41080	HDAC Apoptosis	Cancer
Droxinostat (NS 41080) is a histone deacetylase (HDAC) inhibitor. Droxinostat selectively inhibits HDAC3, HDAC6, and HDAC8 with IC₅₀ values of 16.9 μM, 2.47 μM, and 1.46 μM, respectively. Droxinostat can be used for the research of hepatocellular carcinoma (HCC) .

HY-158308

HDAC6-IN-41	HDAC	Cancer
HDAC6-IN-41 (Compound E24) is a selective inhibitor for histone deacetylase 6 (HDAC6), with IC₅₀ of 14 and 422 nM, for HDAC6 and HDAC8, respectively. HDAC6-IN-41 upregulates the acetylation of α-tubulin and histone site SMC3 .

HY-18613

CAY10603 5+ Cited Publications BML-281	HDAC	Cancer
CAY10603 (BML-281) is a potent and selective *HDAC6* inhibitor, with an IC₅₀ of 2 pM; CAY10603 (BML-281) also inhibits HDAC1, HDAC2, HDAC3, HDAC8, HDAC10, with IC₅₀s of 271, 252, 0.42, 6851, 90.7 nM.

HY-13271A

Tubastatin A Maximum Cited Publications 34 Publications Verification	Beta-lactamase HDAC Autophagy Apoptosis	Cancer
Tubastatin A is a potent and selective *HDAC6* inhibitor with an IC₅₀ of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A also inhibits *HDAC10* and metallo-β-lactamase domain-containing protein 2 (MBLAC2).

HY-173330

HDAC-IN-89	HDAC	Cancer
HDAC-IN-89 is an inhibitor of *HDAC1* (IC₅₀: 0.95 nM), *HDAC2* (IC₅₀: 0.86 nM), *HDAC3* (IC₅₀: 1.06 nM) and *HDAC8* (IC₅₀: 4.24 nM). HDAC-IN-89 blocks the cell cycle and induces apoptosis. HDAC-IN-89 has anti-tumor activity .

HY-151248

HDAC2-IN-1	HDAC	Neurological Disease
HDAC2-IN-1 (Compound 17) is a brain penetrant, orally active, competitive *HDAC2* inhibitor with an IC₅₀ of 0.5 μM . HDAC2-IN-1 also inhibits *HDAC1* and *HDAC8* with IC₅₀s of 1.61 μM and 0.98 μM, respectively .

HY-13271

Tubastatin A Hydrochloride Maximum Cited Publications 34 Publications Verification Tubastatin A HCl; TSA HCl	Beta-lactamase HDAC Autophagy Apoptosis	Cancer
Tubastatin A Hydrochloride (Tubastatin A HCl) is a potent and selective *HDAC6* inhibitor with IC₅₀ of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A Hydrochloride also inhibits *HDAC10* and metallo-β-lactamase domain-containing protein 2 (MBLAC2).

Cat. No.	Product Name	Type

HY-13271AG

Tubastatin A (GMP)

Fluorescent Dye

Tubastatin A (GMP) is the Tubastatin A (HY-13271A) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Tubastatin A is a potent and selective HDAC6 inhibitor with an IC₅₀ of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A also inhibits HDAC10 and metallo-β-lactamase domain-containing protein 2 (MBLAC2).

Cat. No.	Product Name	Type

HY-13271AG

Tubastatin A (GMP)

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-144292

HDAC-IN-30	HDAC	Cancer
HDAC-IN-30 is a novel multi-target *HDAC* inhibitor, including *HDAC1* (IC₅₀=13.4 nM),HDAC2 (IC₅₀=28.0 nM), *HDAC3* (IC₅₀=9.18 nM), *HDAC6* (IC₅₀=42.7 nM), *HDAC8* (IC₅₀=131 nM). HDAC-IN-30 exhibits potent antitumor efficacy .

Cat. No.	Product Name		Classification

HY-163143

HDAC8-IN-6		Alkynes
HDAC8-IN-6 (compound 3) is a potent *HDAC8* inhibitor with an IC₅₀ of 5.1 μM. HDAC8-IN-6 shows cytotoxicity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: